

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 18 U.S.C. §208(b)(3)**

David Harrington, Ph.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: September 6-7, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to (1) New Drug Application (NDA) 20-287, Fragmin (dalteparin sodium injection), sponsored by Pfizer, Inc., for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE)) to reduce the recurrence of VTE in patients with cancer; and (2) NDA 21-660, Abraxane (paclitaxel protein-bound particles for injectable suspension)(albumin-bound), sponsored by Abraxis BioScience, Inc., including trial design issues for adjuvant treatment of node-positive breast cancer, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Related Study	Competitor for issues 1 and 2	Less than \$100,000 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest, the waiver is not valid.

/s/

Signature

8/17/06

Date